Is Mother Nature’s psychedelic toolkit of naturally occurring compounds such as psilocybin, DMT, 5-MeO-DMT and mescaline sufficient as therapies for the emerging psychedelic healthcare movement? Or is there ample room for improvement with “Generation 3” compounds that are are inspired by existing psychedelic scaffolds but nonetheless man-made, synthesized in a lab and potentially more commercially viable? There’s an ongoing debate between pure plant-derived medicine vs. chemically synthesized compounds and which has better therapeutic potential to address mental health disorders and other conditions. This panel seeks to address many of these hot button issues and provide a mechanistic and pharmacological perspective on psychedelic compounds and their analogues.